Another CF drug to target Biofilms

E

enniob

Administrator
Staff member
A New Zealand company is developing a new drug called Citramel, which is claimed to target the biofilms bacteria use to build-up resistance to antibiotics. It just received approved by New Zealand regulators for its use in a clinical study which will start soon pending funding. Citramel is a liquid formulation delivered by nebuliser and inhaled into the lungs of those with CF. The trial is expected to show that Citramel is effective in improving lung function on its own. The advantages of Citramel are expected to include improved FEV1 and enhanced effectiveness of other inhaled CF therapies such as antibiotics.

That's the second new drug in as many weeks that is targeted bacterial biofilms and about to enter clinical trials.

Source: http://www.nzherald.co.nz/business/news/article.cfm?c_id=3&objectid=11330879

Like, comment and share of Facebook: https://www.facebook.com/knowcf/posts/10152838047123777

- Chris
 
M

Mallika

New member
Hi Chris,
Good news. would love to bid bye to antibiotics. Btw here's some info shared by novabiotics.

Q1: How long might this take to hit the market. Subject to positive clinical development, likely 2017.
Q2: How do you plan to market this drug in countries like India. As yet, we are not sure but will firm up those plans in the coming year.
Q3: IS there a chance of drug resistance with Lynovex. None and in fact Lynovex reverses antibiotic resistance in bacteria within CF sputum samples.
 
E

enniob

Administrator
Staff member
Hi Aboveallislove, The idea it to breakdown (melt) the biofilms first and then apply the antibiotics. Biofilms are used by bacteria to field themselves against antibiotics and the human immune system defenses.

Hi Mallika, thank you for the update! Appreciated! 2017 sounds right. I guess then need to complete the clinical trial before they can go to market. Pity it has to take so long to find out if this works or not.

- Chris
 
You must log in or register to reply here.
Top